MLTX MoonLake Immunotherapeutics

$7.17

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 10/2/2025

About MoonLake Immunotherapeutics

No Company Description Available

Website: N/A

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1821586
Address
C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET FL 52, BOSTON, MA, US
Valuation
Market Cap
$2.43B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
5.43
Performance
EPS
$-1.89
Dividend Yield
Profit Margin
0.00%
ROE
-25.10%
Technicals
50D MA
$39.63
200D MA
$46.40
52W High
$58.26
52W Low
$31.42
Fundamentals
Shares Outstanding
63M
Target Price
$77.77
Beta
1.31

MLTX EPS Estimates vs Actual

Estimated
Actual

MLTX News & Sentiment

Sep 30, 2025 • Benzinga NEUTRAL
MoonLake Immunotherapeutics ( MLTX ) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman - MoonLake ( NASDAQ:MLTX )
SAN FRANCISCO, Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Investors in MoonLake Immunotherapeutics ( NASDAQ:MLTX ) saw the price of their shares crater $55.75, or about 90%, after the company announced disastrous VELA-2 trial results for sonelokimab, its highly anticipated treatment for patients with ...
Sep 30, 2025 • Benzinga NEUTRAL
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - MoonLake ( NASDAQ:MLTX )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
Sep 29, 2025 • Benzinga SOMEWHAT-BULLISH
MLTX BREAKING NEWS: BFA Law is Investigating MoonLake Immunotherapeutics ( NASDAQ: MLTX ) for Securities Fraud after Stock Drops 90% on Drug Trial Results, Investors Urged to Contact the Firm - MoonLake ( NASDAQ:MLTX )
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics ( NASDAQ: MLTX ) for potential violations of the federal securities laws.
Sep 29, 2025 • Benzinga SOMEWHAT-BULLISH
MoonLake Immunotherapeutics Stock Plummets - MoonLake ( NASDAQ:MLTX )
MoonLake Immunotherapeutics' ( NASDAQ: MLTX ) stock price fell off a cliff Monday after it reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials. The trials used HiSCR75-a 75% reduction in abscess and inflammatory nodule count with no increase in abscesses or draining tunnels-as ...
Sep 29, 2025 • Benzinga SOMEWHAT-BULLISH
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings - Carnival ( NYSE:CCL ) , Better Home & Finance ( NASDAQ:BETR )
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500 also rose, gaining, 0.13% to 6,652.27. Information technology shares jumped by 0.6% on Monday.
Sep 29, 2025 • Benzinga NEUTRAL
BREAKING: MoonLake Immunotherapeutics Shares Down Over 85%; Investors Should Contact Block & Leviton to Potentially Recover Losses - MoonLake ( NASDAQ:MLTX )
BOSTON, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Block & Leviton is investigating MoonLake Immunotherapeutics ( NASDAQ: MLTX ) for potential securities law violations. Investors who have lost money in their MoonLake Immunotherapeutics investment should contact the firm to learn more about how they ...
Sentiment Snapshot

Average Sentiment Score:

0.191
50 articles with scored sentiment

Overall Sentiment:

Bullish

MLTX Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper:
  • Surprise %: 0.0%
Feb 26, 2025
Dec 31, 2024 (Pre market)
-0.13 Surprise
  • Reported EPS: $-0.72
  • Estimate: $-0.59
  • Whisper:
  • Surprise %: -21.5%
Nov 12, 2024
Sep 30, 2024 (Pre market)
-0.12 Surprise
  • Reported EPS: $-0.56
  • Estimate: $-0.44
  • Whisper:
  • Surprise %: -27.3%
Aug 07, 2024
Jun 30, 2024 (Pre market)
-0.11 Surprise
  • Reported EPS: $-0.39
  • Estimate: $-0.28
  • Whisper:
  • Surprise %: -39.3%
May 07, 2024
Mar 31, 2024 (Pre market)
-0.03 Surprise
  • Reported EPS: $-0.22
  • Estimate: $-0.19
  • Whisper:
  • Surprise %: -15.8%
Feb 29, 2024
Dec 31, 2023 (Pre market)
0.11 Surprise
  • Reported EPS: $-0.12
  • Estimate: $-0.23
  • Whisper:
  • Surprise %: 47.8%
Nov 14, 2023
Sep 30, 2023 (Pre market)
0.05 Surprise
  • Reported EPS: $-0.18
  • Estimate: $-0.23
  • Whisper:
  • Surprise %: 21.7%
Aug 10, 2023
Jun 30, 2023 (Pre market)
0.04 Surprise
  • Reported EPS: $-0.23
  • Estimate: $-0.27
  • Whisper:
  • Surprise %: 14.8%
May 12, 2023
Mar 31, 2023 (Pre market)
0.08 Surprise
  • Reported EPS: $-0.23
  • Estimate: $-0.31
  • Whisper:
  • Surprise %: 25.8%

Financials